Recent News

• 03.03.2025 - Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
• 02.12.2025 - Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
• 12.23.2024 - Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
• 12.23.2024 - Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Recent Filings

• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.29.2025 - EFFECT Notice of Effectiveness
• 01.28.2025 - CORRESP Correspondence
• 01.28.2025 - UPLOAD SEC-generated letter
• 01.28.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.24.2025 - S-3 Registration statement under Securities Act of 1933